| Literature DB >> 20730003 |
M W Z Basalus1, K Tandjung, K G van Houwelingen, M G Stoel, F H A F de Man, J W Louwerenburg, S A M Saïd, G C M Linssen, M A W J Kleijne, J van der Palen, J Huisman, P M J Verhorst, C von Birgelen.
Abstract
Background. New-generation drug-eluting stents (DES) may solve several problems encountered with first-generation DES, but there is a lack of prospective head-to-head comparisons between new-generation DES. In addition, the outcome of regulatory trials may not perfectly reflect the outcome in 'real world' patients.Objectives. To compare the efficacy and safety of two new-generation DES in a 'real world' patient population.Methods. A prospective, randomised, single-blinded clinical trial to evaluate clinical outcome after Endeavor Resolute vs. Xience V stent implantation. The primary endpoint is target vessel failure at one-year follow-up. In addition, the study comprises a two-year and an open-label five-year follow-up. (Neth Heart J 2010;18:360-4.).Entities:
Keywords: Drug-Eluting Stents; Angioplasty, Transliminal, Percutaneous Coronary; Coronary Artery Diseases; Randomized Controlled Trial; Thrombosis
Year: 2010 PMID： 20730003 PMCID： PMC2922782 DOI： 10.1007/BF03091792
Source DB: PubMed Journal: Neth Heart J ISSN： 1568-5888 Impact factor: 2.380